In Vivo Electrochemical Monitoring of Safinamide Pharmacokinetics in the Brain Explores Its Correlation With Vision‐Related Neuronal Activity
Source abstract
Abstract
ABSTRACT Understanding drug pharmacokinetics (PK) at its site of action, particularly in the brain, is essential for accurately evaluating therapeutic efficacy and safety. However, conventional PK assessment based on blood measurements often fails to reflect drug dynamics in the central nervous system (CNS). Here, taking the anti‐Parkinson's drug safinamide (SAF) as an example, we introduce a real‐time in vivo electrochemical sensing strategy with high spatiotemporal resolution, operational simplicity, and excellent reproducibility. Our results reveal that the PK profile of SAF in the substantia nigra (SN) differs markedly from that in plasma, characterized by enhanced brain accumulation and distinct clearance kinetics. By simultaneously monitoring SAF and neuronal activity in the superficial gray layer (SuG) of the superior colliculus (SC), we observed pronounced suppression of neuronal firing at peak SAF levels, followed by gradual recovery during SAF elimination. This tight temporal correlation suggests that transient inhibition of vision‐related neuronal activity may be directly associated with SAF concentration at the site. Overall, our study establishes an electrochemical approach enabling rapid, selective, and real‐time drug monitoring in the living brain, offering a powerful tool to promote mechanistic studies of CNS drug action and safety.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Neurological disorders and treatments · Epilepsy research and treatment · Functional Brain Connectivity Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Natural and Biomimetic Drugs School of Pharmaceutical Sciences Beijing Key Laboratory of Carbohydrate Intelligent Manufacture and Functional Applications Peking University Beijing P. R. China
Funding
Natural Science Foundation of Beijing Municipality · National Natural Science Foundation of China · National Key Research and Development Program of China
References (62)
Show source-provided references
1. 10.1038/s41551‐017‐0118‐510.1038/s41551‐017‐0118‐5 ↗
2. 10.1021/acsptsci.4c0057910.1021/acsptsci.4c00579 ↗
3. 10.3390/biomedicines912183410.3390/biomedicines9121834 ↗
4. 10.1073/pnas.161345811410.1073/pnas.1613458114 ↗
5. 10.1002/bmc.531010.1002/bmc.5310 ↗
6. 10.1021/acschemneuro.1c0003910.1021/acschemneuro.1c00039 ↗
7. 10.1021/jacs.2c1322310.1021/jacs.2c13223 ↗
8. 10.1002/anie.20201019510.1002/anie.202010195 ↗
9. 10.1021/jacs.4c0657210.1021/jacs.4c06572 ↗
10. 10.1021/acs.analchem.4c0249310.1021/acs.analchem.4c02493 ↗
11. 10.1021/ac500622m10.1021/ac500622m ↗
12. 10.1021/jacs.5c2260810.1021/jacs.5c22608 ↗
13. 10.1021/acssensors.3c0208810.1021/acssensors.3c02088 ↗
14. 10.1021/jacs.6b1146910.1021/jacs.6b11469 ↗
15. 10.1039/b807913g10.1039/b807913g ↗
16. 10.1002/anie.20220812110.1002/anie.202208121 ↗
17. 10.1002/anie.20241639510.1002/anie.202416395 ↗
18. 10.1021/acs.analchem.9b0238610.1021/acs.analchem.9b02386 ↗
19. 10.1002/anie.20220739910.1002/anie.202207399 ↗
20. 10.1021/acs.analchem.5c0727810.1021/acs.analchem.5c07278 ↗
21. 10.1016/j.talanta.2024.12563710.1016/j.talanta.2024.125637 ↗
22. 10.1021/jacs.3c0825610.1021/jacs.3c08256 ↗
23. 10.26599/nr.2025.9490744010.26599/nr.2025.94907440 ↗
24. 10.1021/acssensors.3c0126710.1021/acssensors.3c01267 ↗
25. 10.1021/acschemneuro.3c0068710.1021/acschemneuro.3c00687 ↗
26. 10.1021/acschemneuro.1c0067910.1021/acschemneuro.1c00679 ↗
27. 10.1021/acssensors.3c0116510.1021/acssensors.3c01165 ↗
28. 10.1021/ac300354z10.1021/ac300354z ↗
29. 10.1039/d5sc08242k10.1039/d5sc08242k ↗
30. 10.1021/la903799n10.1021/la903799n ↗
31. 10.1007/s40263‐017‐0408‐110.1007/s40263‐017‐0408‐1 ↗
32. 10.1016/j.microc.2022.10790010.1016/j.microc.2022.107900 ↗
33. 10.1038/srep2693810.1038/srep26938 ↗
34. 10.1021/ac00285a06610.1021/ac00285a066 ↗
35. 10.1016/j.bios.2018.09.08210.1016/j.bios.2018.09.082 ↗
36. 10.1021/acs.analchem.0c0222510.1021/acs.analchem.0c02225 ↗
37. 10.1186/2047‐9158‐1‐410.1186/2047‐9158‐1‐4 ↗
38. 10.1016/j.tox.2012.01.00710.1016/j.tox.2012.01.007 ↗
39. 10.1016/s0006‐8993(00)02879‐110.1016/s0006‐8993(00)02879‐1 ↗
40. 10.7554/eLife.8828910.7554/eLife.88289 ↗
41. 10.1159/00035480510.1159/000354805 ↗
42. 10.1002/bdd.182210.1002/bdd.1822 ↗
43. 10.1038/s41551‐025‐01389‐610.1038/s41551‐025‐01389‐6 ↗
44. 10.1016/j.cub.2019.11.07910.1016/j.cub.2019.11.079 ↗
45. 10.1021/acs.analchem.6b0147610.1021/acs.analchem.6b01476 ↗
46. 10.1002/anie.20170590010.1002/anie.201705900 ↗
47. 10.1002/anie.20201067510.1002/anie.202010675 ↗
48. 10.2217/nmt.15.4610.2217/nmt.15.46 ↗
49. 10.1007/s10928‐013‐9314‐410.1007/s10928‐013‐9314‐4 ↗
50. 10.1111/j.1742‐7843.2009.00517.x10.1111/j.1742‐7843.2009.00517.x ↗
51. 10.2147/dddt.S30267310.2147/dddt.S302673 ↗
52. 10.1007/s12264‐022‐00858‐110.1007/s12264‐022‐00858‐1 ↗
53. P. C.BrownPharmacology Review(s): Safinimide(U.S. Food and Drug Administration 2016):207145 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000PharmR.pdf.
54. 10.1007/bf0106271910.1007/bf01062719 ↗
55. 10.1523/jneurosci.2041‐09.200910.1523/jneurosci.2041‐09.2009 ↗
56. 10.1038/s41598‐022‐13759‐010.1038/s41598‐022‐13759‐0 ↗
57. 10.1038/nrn324110.1038/nrn3241 ↗
58. 10.1038/s41467‐022‐32775‐210.1038/s41467‐022‐32775‐2 ↗
59. 10.3390/ijms2315818210.3390/ijms23158182 ↗
60. 10.1016/j.neuron.2021.01.01310.1016/j.neuron.2021.01.013 ↗
61. 10.1146/annurev‐vision‐091517‐03414210.1146/annurev‐vision‐091517‐034142 ↗
62. 10.1021/jacs.0c0901110.1021/jacs.0c09011 ↗